ReGen Biologics' CE-marks CMI (Collagen Meniscus Implant) implant:
This article was originally published in Clinica
Executive Summary
ReGen Biologics has CE-marked its Collagen Meniscus Implant (CMI) system. Franklin Lakes, New Jersey-based ReGen is preparing to launch the CMI in Europe through its existing distribution partnership with SulzerMedica. The CMI system is used in treating tears of the meniscus of the knee and is a resorbable collagen scaffold designed to prevent or delay progressive degenerative changes in the knee joint by acting as surrogate meniscus material subsequent to a partial meniscectomy.
You may also be interested in...
EU: Good News For IVDs And For Future Transparency Of Medtech Compliance
The IVD industry has long been awaiting a further extension of the deadlines for compliance with the IVD Regulation and for the launch date of the Eudamed database to be brought forward.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.